Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.
Iris NoordhoekKai TreunerHein PutterYi ZhangJenna WongElma Meershoek-Klein KranenbargMarjolijn Duijm-de CarpentierCornelis J H van de VeldeCatherine A SchnabelGerrit-Jan LiefersPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
BCI (H/I) predicted preferential benefit from 5 versus 2.5 years of EET and identified patients with improved outcomes from completing 10 years of adjuvant endocrine therapy. Findings expand the clinical utility of BCI (H/I) to a broader range of patients and beyond prognostic risk factors as a predictive endocrine response biomarker for early-stage HR+ breast cancer.